Sorafenib, a multikinase inhibitor targeting VEGFR, PDGFR, c-Kit, and RAF, has been the standard of care for patients with advanced, unresectable HCC for over a decade given its ability to increase patients’ survival [144]. Here, KDR is linked to hepatocellular carcinoma.